INTRODUCTION: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is utilized for peritoneal malignancies and is associated with significant resource use. To address potentially modifiable factors contributing to excessive cost, we sought to determine predictors of high cost of care for patients undergoing CRS/HIPEC. METHODS: An institutional CRS/HIPEC database was queried for adult patients from 2014 to 2018. Cost was defined as cost for the index hospitalization, and high-cost cases were defined as > 75th percentile for cost. Bivariate analyses for cost were performed, and all significant tumor, patient, and surgeon-specific variables were entered in a linear regression for cost. A separate linear regression was performed for length of stay (LOS). RESULTS: In total, 59 patients underwent 61 CRS/HIPEC procedures. The median direct variable cost was $20,509 (16,395-25,240). Median length of stay (LOS) was 8 (7-11.5) days and ICU stay was 1 (1-1.5) day. LOS, length of ICU stay and operative time were predictive of cost. Factors associated with increased LOS were Clavien-Dindo grade II complications and ostomy creation. Patient-related factors, including age and BMI, tumor-related factors, such as PCI and CCR, and surgeon were not predictive of cost nor LOS. DISCUSSION: Our results, the first to identify predictors of high cost of CRS/HIPEC-related care in the US, reveal cost was largely related to length and intensity of care. In turn, these drivers were influenced by complications and operative factors. Future work will focus on identifying an appropriate ERAS protocol following CRS/HIPEC and selection of those patients that may avoid routine ICU admission.
INTRODUCTION: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is utilized for peritoneal malignancies and is associated with significant resource use. To address potentially modifiable factors contributing to excessive cost, we sought to determine predictors of high cost of care for patients undergoing CRS/HIPEC. METHODS: An institutional CRS/HIPEC database was queried for adult patients from 2014 to 2018. Cost was defined as cost for the index hospitalization, and high-cost cases were defined as > 75th percentile for cost. Bivariate analyses for cost were performed, and all significant tumor, patient, and surgeon-specific variables were entered in a linear regression for cost. A separate linear regression was performed for length of stay (LOS). RESULTS: In total, 59 patients underwent 61 CRS/HIPEC procedures. The median direct variable cost was $20,509 (16,395-25,240). Median length of stay (LOS) was 8 (7-11.5) days and ICU stay was 1 (1-1.5) day. LOS, length of ICU stay and operative time were predictive of cost. Factors associated with increased LOS were Clavien-Dindo grade II complications and ostomy creation. Patient-related factors, including age and BMI, tumor-related factors, such as PCI and CCR, and surgeon were not predictive of cost nor LOS. DISCUSSION: Our results, the first to identify predictors of high cost of CRS/HIPEC-related care in the US, reveal cost was largely related to length and intensity of care. In turn, these drivers were influenced by complications and operative factors. Future work will focus on identifying an appropriate ERAS protocol following CRS/HIPEC and selection of those patients that may avoid routine ICU admission.
Authors: P H Sugarbaker; B M Ronnett; A Archer; A M Averbach; R Bland; D Chang; R R Dalton; S E Ettinghausen; P Jacquet; J Jelinek; P Koslowe; R J Kurman; B Shmookler; A D Stephens; M A Steves; O A Stuart; S White; C M Zahn; F A Zoetmulder Journal: Adv Surg Date: 1996
Authors: Eliza W Beal; Ahmed Ahmed; Travis Grotz; Jennifer Leiting; Keith F Fournier; Andrew J Lee; Sean Dineen; Sophie Dessureault; Joel M Baumgartner; Jula Veerapong; Callisia Clarke; Erin Strong; Shishir K Maithel; Mohammad Y Zaidi; Sameer Patel; Vikrom Dhar; Ryan Hendrix; Laura Lambert; Fabian Johnston; Nadege Fackche; Mustafa Raoof; Christopher LaRocca; Sean Ronnekleiv-Kelly; Courtney Pokrzywa; Timothy M Pawlik; Sherif Abdel-Misih; Jordan M Cloyd Journal: Am J Surg Date: 2019-09-19 Impact factor: 2.565
Authors: Nathan M Hinkle; James MacDonald; John P Sharpe; Paxton Dickson; Jeremiah Deneve; Gitonga Munene Journal: Am J Surg Date: 2016-03-21 Impact factor: 2.565
Authors: Malcolm H Squires; Christopher A Staley; William Knechtle; Joshua H Winer; Maria C Russell; Sebastian Perez; John F Sweeney; Shishir K Maithel; Charles A Staley Journal: Ann Surg Oncol Date: 2014-09-24 Impact factor: 5.344
Authors: Femke A van der Zant; Bob J L Kooijman; Judith E K R Hentzen; Wijnand Helfrich; Emily M Ploeg; Robert J van Ginkel; Barbara L van Leeuwen; Lukas B Been; Joost M Klaase; Patrick H J Hemmer; Christian S van der Hilst; Schelto Kruijff Journal: BJS Open Date: 2022-09-02
Authors: Shannon N Radomski; Isabella Florissi; Hamza Khan; Amn Siddiqi; Dane C Paneitz; Fabian M Johnston; Jonathan B Greer Journal: J Surg Oncol Date: 2022-09-08 Impact factor: 2.885